Details of the Drug

General Information of Drug (ID: DM53SRA)

Drug Name
Prochlorperazine
Synonyms
CHLOPERAZINE; Capazine; Chlormeprazine; Chlorperazine; Combid; Compazine; Compro; Emelent; Eskatrol; Kronocin; Meterazin; Meterazine; Nipodal; Novamin; Prochloroperazine; Prochlorpemazine; Prochlorperazin; Prochlorperazinum; Prochlorpermazine; Prochlorpromazine; Procloperazine; Proclorperazina; Proclorperazine; Stemetil; Tementil; Temetid; Vertigon; Compazine Suppositories; Prochlorperazine Edisylate Salt; Prochlorperazine dihydrobromide; Prochlorperazine dimaleate; Prochlorperazine maleate; Prochlorperazine mesilate; Bayer A 173; P77; RP 6140; SKF 4657; Buccastem (TN); Compazine (TN); Compro (TN); Phenotil (TN); Prochlorperazinum [INN-Latin]; Proclorperazina [INN-Spanish]; Stemetil (TN); Stemzine (TN); Compazine (*Maleate*); Prochlorperazine (JAN/USP/INN); Prochlorperazine [USAN:INN:BAN:JAN]; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 2-Chloro-10-[3-(4-methyl-1-piper-azinyl)propyl]-10H-pheno-thiazine dimaleate; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 6140 RP
Indication
Disease Entry ICD 11 Status REF
Nausea MD90 Approved [1], [2]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 373.9
Topological Polar Surface Area (xlogp) 4.9
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 5 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 12.5% [3]
Clearance
The renal clearance of drug is 23.6 mL/h [5]
Elimination
0.1% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 9 - 8 hours [5]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.828 micromolar/kg/day [7]
Vd
The volume of distribution (Vd) of drug is 1401 L [8]
Water Solubility
The ability of drug to dissolve in water is measured as 0.1 mg/mL [4]
Chemical Identifiers
Formula
C20H24ClN3S
IUPAC Name
2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
Canonical SMILES
CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
InChI
InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
InChIKey
WIKYUJGCLQQFNW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4917
ChEBI ID
CHEBI:8435
CAS Number
58-38-8
DrugBank ID
DB00433
TTD ID
D0B2UZ
VARIDT ID
DR00592
INTEDE ID
DR1345
ACDINA ID
D00559

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [9], [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Nausea
ICD Disease Classification MD90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Prochlorperazine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Droperidol. Nausea/vomiting [MD90] [32]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Dimenhydrinate. Nausea/vomiting [MD90] [33]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Promethazine. Nausea/vomiting [MD90] [33]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Cyclizine. Nausea/vomiting [MD90] [33]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Prochlorperazine and Metoclopramide. Nausea/vomiting [MD90] [34]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Dolasetron. Nausea/vomiting [MD90] [32]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Ondansetron. Nausea/vomiting [MD90] [32]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Prochlorperazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Ivosidenib. Acute myeloid leukaemia [2A60] [35]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Midostaurin. Acute myeloid leukaemia [2A60] [32]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Idarubicin. Acute myeloid leukaemia [2A60] [32]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Daunorubicin. Acute myeloid leukaemia [2A60] [32]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Arn-509. Acute myeloid leukaemia [2A60] [36]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Gilteritinib. Acute myeloid leukaemia [2A60] [37]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Oliceridine. Acute pain [MG31] [32]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [38]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [38]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [33]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Memantine. Alzheimer disease [8A20] [33]
Galantamine DMEO794 Moderate Antagonize the effect of Prochlorperazine when combined with Galantamine. Alzheimer disease [8A20] [39]
Rivastigmine DMG629M Moderate Antagonize the effect of Prochlorperazine when combined with Rivastigmine. Alzheimer disease [8A20] [39]
Donepezil DMIYG7Z Moderate Antagonize the effect of Prochlorperazine when combined with Donepezil. Alzheimer disease [8A20] [39]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Prochlorperazine and Metronidazole. Amoebiasis [1A36] [40]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Prochlorperazine and Trimethaphan. Aneurysm/dissection [BD50] [41]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Ivabradine. Angina pectoris [BA40] [36]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Bepridil. Angina pectoris [BA40] [32]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Dronedarone. Angina pectoris [BA40] [32]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Amyl nitrite. Angina pectoris [BA40] [42]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Prochlorperazine and Nifedipine. Angina pectoris [BA40] [42]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [43]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [33]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Cilostazol. Arterial occlusive disease [BD40] [32]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Voriconazole. Aspergillosis [1F20] [32]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Levalbuterol. Asthma [CA23] [44]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Terbutaline. Asthma [CA23] [45]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Pirbuterol. Asthma [CA23] [45]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Salbutamol. Asthma [CA23] [44]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Formoterol. Asthma [CA23] [45]
Lisdexamfetamine DM6W8V5 Moderate Antagonize the effect of Prochlorperazine when combined with Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [46]
Desipramine DMT2FDC Moderate Increased plasma concentrations of Prochlorperazine and Desipramine due to competitive inhibition of the same metabolic pathway. Attention deficit hyperactivity disorder [6A05] [47]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Ofloxacin. Bacterial infection [1A00-1C4Z] [48]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [32]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Clarithromycin. Bacterial infection [1A00-1C4Z] [32]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Prochlorperazine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [32]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [48]
Linezolid DMGFPU2 Moderate Additive CNS depression effects by the combination of Prochlorperazine and Linezolid. Bacterial infection [1A00-1C4Z] [49]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [48]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Levofloxacin. Bacterial infection [1A00-1C4Z] [48]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [32]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Telithromycin. Bacterial infection [1A00-1C4Z] [32]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Retigabine. Behcet disease [4A62] [32]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Cariprazine. Bipolar disorder [6A60] [33]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Prochlorperazine and Loperamide. Bowel habit change [ME05] [50]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Eribulin. Breast cancer [2C60-2C6Y] [32]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Lapatinib. Breast cancer [2C60-2C6Y] [32]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Tamoxifen. Breast cancer [2C60-2C6Y] [32]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Toremifene. Breast cancer [2C60-2C6Y] [32]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Sotalol. Cardiac arrhythmia [BC9Z] [32]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Prochlorperazine when combined with Acetylcholine. Cataract [9B10] [51]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [52]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [45]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [52]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [45]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [52]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [45]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [45]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Isoproterenol. Conduction disorder [BC63] [44]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Prochlorperazine and Olopatadine. Conjunctiva disorder [9A60] [53]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Propofol. Corneal disease [9A76-9A78] [54]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Sevoflurane. Corneal disease [9A76-9A78] [32]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Probucol. Coronary atherosclerosis [BA80] [32]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Clofazimine. Crohn disease [DD70] [55]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Mifepristone. Cushing syndrome [5A70] [32]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Pasireotide. Cushing syndrome [5A70] [32]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Cyclandelate. Dementia [6D80-6D8Z] [42]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Sertraline. Depression [6A70-6A7Z] [32]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Cyclobenzaprine. Depression [6A70-6A7Z] [33]
Imipramine DM2NUH3 Moderate Increased plasma concentrations of Prochlorperazine and Imipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [47]
Fluoxetine DM3PD2C Moderate Additive antidopaminergic effects by the combination of Prochlorperazine and Fluoxetine. Depression [6A70-6A7Z] [56]
Nortriptyline DM4KDYJ Moderate Increased plasma concentrations of Prochlorperazine and Nortriptyline due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [47]
Paroxetine DM5PVQE Moderate Decreased metabolism of Prochlorperazine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [57]
Selegiline DM6034S Moderate Additive CNS depression effects by the combination of Prochlorperazine and Selegiline. Depression [6A70-6A7Z] [49]
Duloxetine DM9BI7M Moderate Decreased metabolism of Prochlorperazine caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [58]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Prochlorperazine and Isocarboxazid. Depression [6A70-6A7Z] [49]
Tranylcypromine DMGB5RE Moderate Additive CNS depression effects by the combination of Prochlorperazine and Tranylcypromine. Depression [6A70-6A7Z] [49]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Prochlorperazine and OPC-34712. Depression [6A70-6A7Z] [33]
Phenelzine DMHIDUE Moderate Additive CNS depression effects by the combination of Prochlorperazine and Phenelzine. Depression [6A70-6A7Z] [49]
Clomipramine DMINRKW Moderate Increased plasma concentrations of Prochlorperazine and Clomipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [47]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Trazodone. Depression [6A70-6A7Z] [59]
Amoxapine DMKITQE Moderate Increased plasma concentrations of Prochlorperazine and Amoxapine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [47]
Doxepin DMPI98T Moderate Increased plasma concentrations of Prochlorperazine and Doxepin due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [60]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Maprotiline. Depression [6A70-6A7Z] [33]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Prochlorperazine and Esketamine. Depression [6A70-6A7Z] [40]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Nitroglycerin. Diabetic foot ulcer [BD54] [42]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Mepenzolate. Digestive system disease [DE2Z] [33]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Oxybutynine. Discovery agent [N.A.] [33]
Tetrabenazine DMYWQ0O Major Additive antidopaminergic effects by the combination of Prochlorperazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [61]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Meclizine. Dizziness and giddiness [MB48] [33]
Deutetrabenazine DMUPFLI Major Additive antidopaminergic effects by the combination of Prochlorperazine and Deutetrabenazine. Dystonic disorder [8A02] [62]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Ingrezza. Dystonic disorder [8A02] [63]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Prochlorperazine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [64]
Stiripentol DMMSDOY Moderate Decreased metabolism of Prochlorperazine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [65]
Guanabenz DM5QWEL Moderate Additive hypotensive effects by the combination of Prochlorperazine and Guanabenz. Essential hypertension [BA00] [42]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Prochlorperazine and Ethacrynic acid. Essential hypertension [BA00] [41]
Bendroflumethiazide DM7EVLC Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Bendroflumethiazide. Essential hypertension [BA00] [40]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Prochlorperazine and Phenoxybenzamine. Essential hypertension [BA00] [42]
Nicardipine DMCDYW7 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Nicardipine. Essential hypertension [BA00] [42]
Mecamylamine DMGQFYB Moderate Additive hypotensive effects by the combination of Prochlorperazine and Mecamylamine. Essential hypertension [BA00] [42]
Benzthiazide DMQWZ0H Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Benzthiazide. Essential hypertension [BA00] [40]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Prochlorperazine and Nadolol. Essential hypertension [BA00] [42]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Solifenacin. Functional bladder disorder [GC50] [32]
Mirabegron DMS1GYT Moderate Decreased metabolism of Prochlorperazine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [66]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Tolterodine. Functional bladder disorder [GC50] [33]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Prochlorperazine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [67]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Pentamidine. Fungal infection [1F29-1F2F] [32]
Terbinafine DMI6HUW Moderate Decreased metabolism of Prochlorperazine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [68]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Ketoconazole. Fungal infection [1F29-1F2F] [32]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Prochlorperazine and Phentolamine. Gangrene [MC85] [42]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Cisapride. Gastro-oesophageal reflux disease [DA22] [32]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [32]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Prochlorperazine when combined with Isoflurophate. Glaucoma [9C61] [51]
Carteolol DMFMDOB Moderate Additive hypotensive effects by the combination of Prochlorperazine and Carteolol. Glaucoma [9C61] [42]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Prochlorperazine and Brimonidine. Glaucoma [9C61] [69]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Prochlorperazine when combined with Pilocarpine. Glaucoma [9C61] [51]
Prazosin DMCD9YG Moderate Additive hypotensive effects by the combination of Prochlorperazine and Prazosin. Heart failure [BD10-BD1Z] [42]
Eplerenone DMF0NQR Moderate Additive hypotensive effects by the combination of Prochlorperazine and Eplerenone. Heart failure [BD10-BD1Z] [42]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Prochlorperazine and Carvedilol. Heart failure [BD10-BD1Z] [42]
Chlorothiazide DMLHESP Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Chlorothiazide. Heart failure [BD10-BD1Z] [40]
Furosemide DMMQ8ZG Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Furosemide. Heart failure [BD10-BD1Z] [40]
Amiloride DMRTSGP Moderate Additive hypotensive effects by the combination of Prochlorperazine and Amiloride. Heart failure [BD10-BD1Z] [42]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Bumetanide. Heart failure [BD10-BD1Z] [40]
Hydroflumethiazide DMVPUQI Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [40]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Procarbazine. Hodgkin lymphoma [2B30] [49]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [70]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Prochlorperazine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [71]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [72]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [73]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [32]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Isosorbide mononitrate. Hydrocephalus [8D64] [42]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Prochlorperazine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [40]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Prochlorperazine and Eprosartan. Hypertension [BA00-BA04] [42]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Prochlorperazine and Acebutolol. Hypertension [BA00-BA04] [42]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Prochlorperazine and Moexipril. Hypertension [BA00-BA04] [42]
Bisoprolol DM3UZ95 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Bisoprolol. Hypertension [BA00-BA04] [42]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Prochlorperazine and Captopril. Hypertension [BA00-BA04] [42]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Prochlorperazine and Penbutolol. Hypertension [BA00-BA04] [42]
Trandolapril DM4L6EU Moderate Additive hypotensive effects by the combination of Prochlorperazine and Trandolapril. Hypertension [BA00-BA04] [42]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Methyldopa. Hypertension [BA00-BA04] [42]
Clonidine DM6RZ9Q Moderate Additive hypotensive effects by the combination of Prochlorperazine and Clonidine. Hypertension [BA00-BA04] [42]
Losartan DM72JXH Moderate Additive hypotensive effects by the combination of Prochlorperazine and Losartan. Hypertension [BA00-BA04] [42]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Prochlorperazine and Nebivolol. Hypertension [BA00-BA04] [42]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Prochlorperazine and Levamlodipine. Hypertension [BA00-BA04] [42]
Fosinopril DM9NJ52 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Fosinopril. Hypertension [BA00-BA04] [42]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Prochlorperazine and Doxazosin. Hypertension [BA00-BA04] [42]
Verapamil DMA7PEW Moderate Additive hypotensive effects by the combination of Prochlorperazine and Verapamil. Hypertension [BA00-BA04] [42]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Prochlorperazine and TAK-491. Hypertension [BA00-BA04] [42]
Pindolol DMD2NV7 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Pindolol. Hypertension [BA00-BA04] [42]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Prochlorperazine and Fenoldopam. Hypertension [BA00-BA04] [42]
Indapamide DMGN1PW Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Indapamide. Hypertension [BA00-BA04] [40]
Benazepril DMH1M9B Moderate Additive hypotensive effects by the combination of Prochlorperazine and Benazepril. Hypertension [BA00-BA04] [42]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Prochlorperazine and Trichlormethiazide. Hypertension [BA00-BA04] [42]
Labetalol DMK8U72 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Labetalol. Hypertension [BA00-BA04] [42]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Diazoxide. Hypertension [BA00-BA04] [42]
Enalapril DMNFUZR Moderate Additive hypotensive effects by the combination of Prochlorperazine and Enalapril. Hypertension [BA00-BA04] [42]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Prochlorperazine and Perindopril. Hypertension [BA00-BA04] [42]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Felodipine. Hypertension [BA00-BA04] [42]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Quinapril. Hypertension [BA00-BA04] [42]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Prochlorperazine and Deserpidine. Hypertension [BA00-BA04] [42]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Telmisartan. Hypertension [BA00-BA04] [42]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Prochlorperazine and Irbesartan. Hypertension [BA00-BA04] [42]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Prochlorperazine and Hydralazine. Hypertension [BA00-BA04] [42]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Prochlorperazine and Lisinopril. Hypertension [BA00-BA04] [42]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Hydrochlorothiazide. Hypertension [BA00-BA04] [40]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Clevidipine butyrate. Hypertension [BA00-BA04] [42]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Belladonna. Infectious gastroenteritis/colitis [1A40] [33]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Amantadine. Influenza [1E30-1E32] [74]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Propiomazine. Insomnia [7A00-7A0Z] [33]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Prochlorperazine and ITI-007. Insomnia [7A00-7A0Z] [33]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [32]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Phenolphthalein. Irritable bowel syndrome [DD91] [32]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Clidinium. Irritable bowel syndrome [DD91] [33]
Physostigmine DM2N0TO Moderate Antagonize the effect of Prochlorperazine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [39]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Prochlorperazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [36]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Crizotinib. Lung cancer [2C25] [75]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Prochlorperazine and Porfimer Sodium. Lung cancer [2C25] [76]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Ceritinib. Lung cancer [2C25] [32]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Osimertinib. Lung cancer [2C25] [77]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Selpercatinib. Lung cancer [2C25] [36]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Lumefantrine. Malaria [1F40-1F45] [40]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Halofantrine. Malaria [1F40-1F45] [78]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Chloroquine. Malaria [1F40-1F45] [79]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Hydroxychloroquine. Malaria [1F40-1F45] [79]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Quinine. Malaria [1F40-1F45] [32]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Primaquine. Malaria [1F40-1F45] [32]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [36]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [80]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Vemurafenib. Melanoma [2C30] [32]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and LGX818. Melanoma [2C30] [81]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Prochlorperazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [82]
Propranolol DM79NTF Moderate Additive hypotensive effects by the combination of Prochlorperazine and Propranolol. Migraine [8A80] [42]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Prochlorperazine and Lasmiditan. Migraine [8A80] [83]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Prochlorperazine and Flibanserin. Mood disorder [6A60-6E23] [84]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Panobinostat. Multiple myeloma [2A83] [85]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Prochlorperazine and Thalidomide. Multiple myeloma [2A83] [86]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Fingolimod. Multiple sclerosis [8A40] [32]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Ozanimod. Multiple sclerosis [8A40] [87]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Prochlorperazine and Methoxsalen. Mycosis fungoides [2B01] [40]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Romidepsin. Mycosis fungoides [2B01] [32]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Nilotinib. Myeloproliferative neoplasm [2A20] [32]
Imatinib DM7RJXL Moderate Decreased metabolism of Prochlorperazine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [88]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Prochlorperazine when combined with Dextroamphetamine. Narcolepsy [7A20] [46]
Bupropion DM5PCS7 Major Decreased metabolism of Prochlorperazine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [32]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Entrectinib. Non-small cell lung cancer [2C25] [40]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Prochlorperazine when combined with Phendimetrazine. Obesity [5B80-5B81] [46]
Amfepramone DM9YSNQ Moderate Antagonize the effect of Prochlorperazine when combined with Amfepramone. Obesity [5B80-5B81] [46]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Prochlorperazine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [89]
Benzphetamine DMIJATC Moderate Antagonize the effect of Prochlorperazine when combined with Benzphetamine. Obesity [5B80-5B81] [46]
Mazindol DMZ36RN Moderate Antagonize the effect of Prochlorperazine when combined with Mazindol. Obesity [5B80-5B81] [46]
Metolazone DMB39LO Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Metolazone. Oedema [MG29] [40]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Polythiazide. Oedema [MG29] [40]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Levomethadyl Acetate. Opioid use disorder [6C43] [36]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Lofexidine. Opioid use disorder [6C43] [32]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Prochlorperazine and Apraclonidine. Optic nerve disorder [9C40] [69]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Rucaparib. Ovarian cancer [2C73] [32]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Prochlorperazine and Dextropropoxyphene. Pain [MG30-MG3Z] [90]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Flavoxate. Pain [MG30-MG3Z] [33]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Prochlorperazine when combined with Methamphetamine. Pain [MG30-MG3Z] [91]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Prochlorperazine and Buprenorphine. Pain [MG30-MG3Z] [92]
Meperidine DMX4GND Moderate Additive CNS depression effects by the combination of Prochlorperazine and Meperidine. Pain [MG30-MG3Z] [93]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Triclabendazole. Parasitic worm infestation [1F90] [32]
Pergolide DM14MAE Moderate Antagonize the effect of Prochlorperazine when combined with Pergolide. Parkinsonism [8A00] [94]
Opicapone DM1BKA6 Moderate Antagonize the effect of Prochlorperazine when combined with Opicapone. Parkinsonism [8A00] [94]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Rasagiline. Parkinsonism [8A00] [49]
Biperiden DME78OA Moderate Antagonize the effect of Prochlorperazine when combined with Biperiden. Parkinsonism [8A00] [95]
Entacapone DMLBVKQ Moderate Antagonize the effect of Prochlorperazine when combined with Entacapone. Parkinsonism [8A00] [94]
Levodopa DMN3E57 Moderate Antagonize the effect of Prochlorperazine when combined with Levodopa. Parkinsonism [8A00] [94]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Pimavanserin. Parkinsonism [8A00] [96]
Bromocriptine DMVE3TK Moderate Antagonize the effect of Prochlorperazine when combined with Bromocriptine. Parkinsonism [8A00] [94]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Orphenadrine. Parkinsonism [8A00] [33]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Methylscopolamine. Peptic ulcer [DA61] [33]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Famotidine. Peptic ulcer [DA61] [40]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [97]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Ritodrine. Preterm labour/delivery [JB00] [45]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Degarelix. Prostate cancer [2C82] [36]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Prochlorperazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [98]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Nilutamide. Prostate cancer [2C82] [36]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Enzalutamide. Prostate cancer [2C82] [36]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Flutamide. Prostate cancer [2C82] [36]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Relugolix. Prostate cancer [2C82] [36]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Bicalutamide. Prostate cancer [2C82] [36]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Prochlorperazine and Terazosin. Prostate hyperplasia [GA90] [42]
Tamsulosin DM5QF9V Moderate Additive hypotensive effects by the combination of Prochlorperazine and Tamsulosin. Prostate hyperplasia [GA90] [42]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Silodosin. Prostate hyperplasia [GA90] [42]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Prochlorperazine and Verteporfin. Psoriasis [EA90] [36]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Levomepromazine. Psychotic disorder [6A20-6A25] [33]
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Fluphenazine. Psychotic disorder [6A20-6A25] [33]
Triflupromazine DMKFQJP Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Triflupromazine. Psychotic disorder [6A20-6A25] [33]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Prochlorperazine and Tolazoline. Pulmonary hypertension [BB01] [42]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [99]
Neupro DMHEAB1 Moderate Antagonize the effect of Prochlorperazine when combined with Neupro. Restless legs syndrome [7A80] [94]
Celecoxib DM6LOQU Moderate Decreased metabolism of Prochlorperazine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [100]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Cyproheptadine. Rheumatoid arthritis [FA20] [33]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Quetiapine. Schizophrenia [6A20] [32]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Mesoridazine. Schizophrenia [6A20] [32]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Thioridazine. Schizophrenia [6A20] [101]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Aripiprazole. Schizophrenia [6A20] [33]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Iloperidone. Schizophrenia [6A20] [32]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Paliperidone. Schizophrenia [6A20] [32]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Haloperidol. Schizophrenia [6A20] [32]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Perphenazine. Schizophrenia [6A20] [33]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Molindone. Schizophrenia [6A20] [33]
Chlorpromazine DMBGZI3 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Chlorpromazine. Schizophrenia [6A20] [33]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Thiothixene. Schizophrenia [6A20] [33]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Trifluoperazine. Schizophrenia [6A20] [33]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Risperidone. Schizophrenia [6A20] [33]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Amisulpride. Schizophrenia [6A20] [102]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Asenapine. Schizophrenia [6A20] [32]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Pimozide. Schizophrenia [6A20] [36]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Vardenafil. Sexual dysfunction [HA00-HA01] [32]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Prochlorperazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [32]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [32]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [32]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [36]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [32]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Pitolisant. Somnolence [MG42] [32]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [32]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Adenosine. Supraventricular tachyarrhythmia [BC81] [32]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Lenvatinib. Thyroid cancer [2D10] [32]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Cabozantinib. Thyroid cancer [2D10] [36]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Prochlorperazine and Papaverine. Tonus and reflex abnormality [MB47] [42]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Prochlorperazine and Tizanidine. Tonus and reflex abnormality [MB47] [103]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Tacrolimus. Transplant rejection [NE84] [32]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Atropine. Unspecific substance harmful effect [NE6Z] [33]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Astemizole. Vasomotor/allergic rhinitis [CA08] [32]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [33]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [33]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [33]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [38]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [33]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [33]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Azatadine. Vasomotor/allergic rhinitis [CA08] [33]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Procainamide. Ventricular tachyarrhythmia [BC71] [32]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Propafenone. Ventricular tachyarrhythmia [BC71] [32]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Flecainide. Ventricular tachyarrhythmia [BC71] [32]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Amiodarone. Ventricular tachyarrhythmia [BC71] [32]
⏷ Show the Full List of 297 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Aluminum lake E00504 9989226 Other agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Prochlorperazine 10 mg tablet 10 mg Oral Tablet Oral
Prochlorperazine 5 mg tablet 5 mg Oral Tablet Oral
Prochlorperazine Maleate 5mg tablet 5mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7279).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040058.
3 Prochlorperazine Prescribing Information - AA Pharma
4 BDDCS applied to over 900 drugs
5 Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol. 1991 Dec;32(6):677-84.
6 Prochlorperazine - National Library of Medicine HSDB Database
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Taylor WB, Bateman DN: Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers. Br J Clin Pharmacol. 1987 Feb;23(2):137-42. doi: 10.1111/j.1365-2125.1987.tb03021.x.
9 In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. Int J Pharm. 2009 Feb 23;368(1-2):98-102.
10 Tardive dyskinesia as a result of long-term prochlorperazine use. South Med J. 1996 Oct;89(10):989-91.
11 Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol. 2004 Apr;57(4):464-72.
12 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
13 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
14 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
18 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
19 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
20 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
21 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
22 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
23 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
24 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
25 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
26 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
28 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
29 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
30 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
31 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
32 Canadian Pharmacists Association.
33 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
34 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
35 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
36 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
37 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
38 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
39 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
40 Cerner Multum, Inc. "Australian Product Information.".
41 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
42 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
43 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
44 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
45 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
46 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
47 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
48 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
49 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
50 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
51 Multum Information Services, Inc. Expert Review Panel.
52 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
53 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
54 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
55 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
56 Avenoso A, Spina E, Campo G, Facciola G, Ferlito M, Zuccaro P, Perucca E, Caputi AP "Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications." Pharmacol Res 35 (1997): 335-9. [PMID: 9264051]
57 Nicholson SD "Extra pyramidal side effects associated with paroxetine." West Engl Med J 107 (1992): 90-1. [PMID: 1308691]
58 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
59 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
60 Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
61 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
62 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
63 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
64 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
65 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
66 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
67 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
68 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
69 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
70 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
71 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
72 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
73 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
74 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
75 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
76 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
77 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
78 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
79 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
80 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
81 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
82 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
83 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
84 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
85 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
86 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
87 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
88 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
89 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
90 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
91 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
92 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
93 Lambertsen CJ, Wendel H, Longenhagen JB "The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2." J Pharmacol Exp Ther 131 (1961): 381-93. [PMID: 13758472]
94 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
95 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
96 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
97 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
98 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
99 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
100 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
101 Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
102 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
103 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.